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Smoking tobacco is responsible for a large burden of premature 
mortality, causing about 4.8 million adult deaths worldwide 
in 2000.1 This is expected to increase to about 10 million by 
2025.2 Smoking causes many diseases, including lung cancer, 
other cancers, chronic obstructive pulmonary disease (COPD) 
and cardiovascular disease (CVD), with lung cancer having 
the strongest association and CVD accounting for the majority 
of tobacco-attributable deaths in developed countries.3 Recent 
studies in developing countries such as China,4,5 India6,7 and 
South Africa8,9 suggest that the causes of tobacco-attributable 
mortality may differ in developing countries, with chronic 
respiratory diseases accounting for a larger proportion of 
deaths than in developed countries, and tuberculosis (largely 
eradicated in developed countries) accounting for a significant 
number of deaths.   
After increasing steadily during the 20th century, and 
especially after World War II, annual per capita consumption 
of cigarettes peaked in South Africa at around 1 650 cigarettes 
per adult in the 1980s. Government has taken bold steps 
to discourage tobacco use, to protect non-smokers from 
environmental tobacco smoke, and to protect children 
from pro-smoking advertising messages.10 Comprehensive 
legislation passed in 199910 included the printing of warnings 
on cigarette packaging and advertising material, banning of 
tobacco advertising, sponsorships and promotions, restriction 
of smoking in enclosed public places, and setting maximum 
limits on nicotine and tar yields of cigarettes. Rapid increases 
in the excise tax on cigarettes increased the average retail 
price from R2.55 in 1993 to around R12.50 per pack in 2005, 
and has contributed to the precipitous drop in annual per 
capita cigarette consumption to current levels of less than 800 
cigarettes per adult through significant reductions in smoking 
prevalence and a reduction in cigarette consumption among 
remaining smokers.11,12 The overall prevalence of smoking has 
declined from 32% in 1992 to 24% in 2003.11,12  
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Objectives. To quantify the burden of disease attributable to 
smoking in South Africa for 2000.
Design. The absolute difference between observed lung 
cancer death rate and the level in non-smokers, adjusted 
for occupational and indoor exposure to lung carcinogens, 
was used to estimate the proportion of lung cancer deaths 
attributable to smoking and the smoking impact ratio (SIR). The 
SIR was substituted for smoking prevalence in the attributable 
fraction formula for chronic obstructive pulmonary disease 
(COPD) and cancers to allow for the long lag between exposure 
and outcome. Assuming a shorter lag between exposure and 
disease, the current prevalence of smoking was used to estimate 
the population-attributable fractions (PAF) for the other 
outcomes. Relative risks (RR) from the American Cancer Society 
cancer prevention study (CPS-II) were used to calculate PAF.
Setting. South Africa.
Outcome measures. Deaths and disability-adjusted life years 
(DALYs) due to lung and other cancers, COPD, cardiovascular 
conditions, respiratory tuberculosis, and other respiratory and 
medical conditions.
Results. Smoking caused between 41 632 and 46 656 deaths in 
South Africa, accounting for 8.0 - 9.0% of deaths and 3.7 - 4.3% 
of DALYs in 2000. Smoking ranked third (after unsafe sex/
sexually transmitted disease and high blood pressure) in terms 
of mortality among 17 risk factors evaluated. Three times as 
many males as females died from smoking. Lung cancer had 
the largest attributable fraction due to smoking. However, 
cardiovascular diseases accounted for the largest proportion of 
deaths attributed to smoking.  
Conclusion. Cigarette smoking accounts for a large burden of 
preventable disease in South Africa. While the government has 
taken bold legislative action to discourage tobacco use since 
1994, it still remains a major public health priority. 
S Afr Med J 2007; 97: 674-681.
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Smoking prevalence varies by population group and gender. 
(The population group classification is used in this article 
to demonstrate differences in the risk factor profile and the 
subsequent burden. Data are based on self-reported categories 
according to the population group categories used by Statistics 
South Africa. Such mentioning of differences allows for a 
more accurate estimate of the overall burden and may assist 
in higher effectiveness of future interventions. The authors 
do not subscribe to this classification for any other purpose.) 
Rates are highest among coloured males and females, rates 
for black African females are much lower than those for black 
African males, and the white community has intermediate 
rates.13,14 Prevalence has decreased most rapidly among males, 
black Africans, coloureds, young people aged 16 - 24, and 
low income earners.11,12 Groups that experienced moderate or 
no decreases in smoking prevalence include women, whites, 
Indians and people aged 50 years and older. 
Consistent mortality trend data are not available, with little 
information for blacks before 1999. Data from 1949 to 1985 for 
the other population groups show that lung cancer mortality 
rates have increased markedly among males, with the rates 
among whites increasing almost threefold – and even more for 
coloured males.15 Smaller increases occurred among females. In 
1984 - 1986 the age-standardised mortality for lung cancer was 
highest among urban coloured males (88.4/100 000), followed 
by white urban males (48.7/100 000), urban black African 
males (27.9/100 000) and urban Indian males (21.8/100 000).15 
A similar pattern is seen in the national age-standardised death 
rates for 2000, with coloured males (77.1 per 100 000) having 
the highest rates followed by white males (52.3), coloured 
females (38.8), black males (31.1), white females (30.1), Indian 
males (27.5), black African females (6.3), and lastly Indian 
females (5.6).16 Importantly, lung cancer rates in younger 
black African males aged 35 - 44 years and 45 - 54 years were 
higher than for white males in the same age groups, but much 
lower in older age groups. This suggests that occurrence of 
lung cancer in black Africans may exceed that in whites as 
the cohort of black African smokers ages. In 1988 Yach and 
Joubert17 identified the potential for a rise in mortality from 
smoking-related conditions among coloureds and black 
Africans with increased tobacco use.
Given the high exposure to smoking and large burden 
due to lung cancer, it is likely that tobacco accounts for a 
large proportion of premature mortality in the South African 
population, and will continue to do so in the future. Sitas et al.8 
used a case-control analysis of death notification forms in 1998 
which included the smoking status of the deceased to estimate 
the increased risk of mortality associated with tobacco in South 
Africa. Using direct calculations it was estimated that about 
8% of adult deaths (> 25 years) could be attributed to smoking. 
However, this study was subject to the limitations of a case-
control study and could not adjust for all confounding factors.
The comparative risk assessment (CRA) methodology 
developed by the World Health Organization for the global 
burden of tobacco-attributed mortality used an indirect 
approach, developed by Peto et al.,3 that allows for an 
adjustment for the maturity of the tobacco epidemic through 
a smoking impact ratio (SIR). This method has been refined 
for use in developing countries to take into account the role of 
indoor air pollution from coal smoke in lung cancer mortality.1 
The present study applied an indirect technique to quantify 
the burden of disease attributed to smoking among adults 
for South Africa in 2000, taking into account the variations 
between population groups.
Methods  
Smoking prevalence data were obtained from the 1998 
Demographic and Health Survey.18 A fourth-order polynomial 
was used to smooth the age-specific prevalence observed 
for each race and gender group. For Indian women the 
combination of a small sample and low smoking prevalence 
(9%) resulted in extremely erratic estimates. Since the lifestyle 
of Indians is more similar to that of whites than other 
population groups, the smoking prevalence percentage by age 
among Indian women was scaled to the age pattern of white 
women, such that the average smoking prevalence among 
Indian women remained at 9.0 %. 
Adverse health outcomes related to tobacco use have been 
well described in the literature, and are summarised in Table 
I.3,19 Outcomes likely to be causal, but not quantified in this 
study because of a lack of sufficient evidence on prevalence 
or hazard size (or both), include maternal and perinatal 
conditions and fire injuries. 
There are several sources of relative risk estimates for cause-
specific mortality related to tobacco use, including: (i) the 
American Cancer Society Cancer Prevention Study, Phase II 
(CPS-II) as used by Peto et al.;3 (ii) a retrospective case control 
study of 1 million deaths in urban and rural China;4 (iii) a 
similar case-control study of 43 000 adult male deaths in India;6 
and (iv) a case-control analysis to estimate tobacco-attributed 
mortality in South Africa from 5 340 death notification forms 
which included information on smoking status.8 The CPS-II 
study is a prospective cohort study of smoking and death in 
more than 1 million Americans aged above 30 years in which 
most  current smokers were lifelong cigarette smokers with 
a mean consumption of about 20 cigarettes per day.3 The 
relative risks from the CPS-II study as used by Peto et al.3 and 
Ezzati and Lopez1 were selected as the best point estimates 
to calculate population-attributable fractions (PAF) as these 
were considered to be the most robust. The relative risk (RR) 
estimates, after adjustment for excess risk due to confounding, 
and their 95% confidence intervals (CIs), based on those 
estimated by Thun et al.,21 are set out in Table II.  
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The method to estimate the PAF used by Ezzati et al.1 
has been adapted and applied to South African data. The 
proportion of lung cancer attributable to smoking for each 
population group is estimated as the absolute difference 
between the observed lung cancer death rate and the level 
among non-smokers from the CPS-II study population, once 
the observed rate has been adjusted for occupational and 
indoor exposure to lung carcinogens.22,23 The proportion of 
lung cancer estimated to be attributable to occupational and 
indoor exposure to lung carcinogens is subtracted from the 
Table I.  Disease outcomes related to tobacco use
Outcomes     ICD-10 codes20
Respiratory tuberculosis    A15, A16, A19
Other respiratory diseases    J00-J22, H65-H66, J30-J39, J45-J47, J60-J80, J82-J89, J91-J98
Chronic obstructive pulmonary disease   I27, J40-J44
Lung cancer     C33-C34
Upper aero-digestive cancers    
(oral, pharynx, larynx, oesophagus, sinus cancer)  C00-C14, C15, C30-C32
Digestive, urinary, cervical cancer   C16-C26, C53, C64-C68
Other cancers     C37-C45, C47-C52, C54-C63, C69-C97
Ischaemic heart disease     I20-I25
Stroke and other vascular conditions   I10-I15, I26, I28, I47-I49, I60-I84, I86-I89
Other medical conditions*    D50-D89, E00-E90, Rest of I00-I99, K00-K93, L00-L99, M00-M99, N00-N99
*Excluded: Infectious and parasitic conditions with the exception of the above (rest of A00-B99, N70-N73), maternal and perinatal conditions (O00-O99), neuropsychiatric conditions (F00-
F99, G00-G99), cirrhosis of the liver (K70, K74), congenital anomalies (Q00-Q99), and injuries (V01-Y98). 
ICD-10 = International Classification of Diseases.20
Table II. Relative risk estimates for tobacco-attributable mortality, after adjustment for confounding*
Disease outcome         Male (95% CI)       Female (95% CI)
Lung cancer†                         24.2              12.5
Upper aero-digestive cancer       5.81 (4.2 - 8.23)        5.17 (3.75 - 7.26)
Other cancer      1.48 (1.26 - 1.79)         1.14 (1.05 -1.31)
Chronic obstructive pulmonary disease  9.97 (7.77 - 12.81)     10.25 (7.76 - 12.62)
Other respiratory        
   35 - 59 yrs      2.44 (1.80 - 3.24)        2.18 (1.69 - 2.77)
   60 - 69 yrs      1.84 (1.47 - 2.31)        2.12 (1.65 - 2.68)
   70 - 79 yrs       1.7 (1.39 - 2.09)          1.7 (1.41 - 2.05)
   80+ yrs        1.38 (1.21 -1.59)        1.31 (1.18 - 1.47)
Respiratory tuberculosis   
   35 - 59 yrs      2.44 (1.80 - 3.24)        2.18 (1.69 - 2.77)
   60 - 69 yrs      1.84 (1.47 - 2.31)        2.12 (1.65 - 2.68)
   70 - 79 yrs        1.7 (1.39 - 2.09)          1.7 (1.41 - 2.05)
   80+ yrs        1.38 (1.21 -1.59)        1.31 (1.18 - 1.47)
Ischaemic heart disease   
   35 - 59 yrs      2.44 (2.26 - 2.71)        2.18 (1.97 - 2.39)
   60 - 69 yrs      1.84 (1.74 - 2.00)        2.12 (1.92 - 2.32)
   70 - 79 yrs       1.7  (1.42 - 1.84)               1.7 (1.6 -1.9)
   80+ yrs       1.38 (1.23 - 1.46)        1.31 (1.27 - 1.40)
Stroke   
   35 - 59 yrs      2.44 (2.26 - 2.71)        2.18 (1.97 - 2.39)
   60 - 69 yrs      1.84 (1.74 - 2.00)        2.12 (1.92 - 2.32)
   70 - 79 yrs       1.7  (1.42 - 1.84)              1.7 (1.6 - 1.9)
   80+ yrs       1.38 (1.23 - 1.46)        1.31 (1.27 - 1.40)
Other medical conditions 
   35 - 59 yrs      2.03 (1.57 - 2.60)          1.85 (1.5 - 2.28)
   60 - 69 yrs       1.6  (1.33 - 1.93)           1.8  (1.47 - 2.2)
   70 - 79 yrs        1.5 (1.28 - 1.78)         1.5  (1.29 - 1.75)
   80+ yrs       1.27 (1.15 - 1.42)        1.22  (1.13 - 1.33)
Source: CPS-II relative risk estimates used by Peto et al.3 
*A correction factor of 30% was used to reduce excess risk due to confounding for all cause-specific relative risks, except ‘other medical conditions’ where a correction factor of 50% was 
used.1 
†For lung cancer the PAF was obtained by subtracting the non-smoker lung cancer mortality from the lung cancer mortality of the population, therefore no correction factor was applied 
to the relative risk.  
CI = confidence interval.
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observed age-specific lung cancer mortality rate by gender and 
population group.  
The observed lung cancer mortality rates for each of the 
4 population groups in South Africa were estimated from a 
sample of the official death data for 2000.24 These rates were 
adjusted so that the total of the 4 population groups matched 
the national lung cancer rates from the revised South African 
National Burden of Disease Study estimates for 2000,16 where 
no information was available on race, in order to maintain 
consistency with estimates used for the health outcomes for 
other risk factors studied. 
Since the current prevalence of smoking is a poor proxy 
for the cumulative hazards of smoking, Peto et al.3  proposed 
the SIR, which estimates excess lung cancer, as a marker for 
accumulated smoking risk. In contrast to the global study,1 the 
SIR is substituted for smoking prevalence in the classic PAF 
formula: 
(where P is the prevalence of exposure and RR is the relative 
risk of disease given exposure) only for conditions with a long 
lag between exposure and outcome such as COPD and other 
cancers. The SIR was calculated for all 4 population groups as 
follows:
where CLC is the observed lung cancer rate in a given age 
group in a population, NLC is the non-smoker lung cancer rate 
in the study population, and S*LC and N*LC are the smoker and 
non-smoker lung cancer rates in a reference population from 
the CPS-II study population.3  The SIR point estimates were 
smoothed using appropriate polynomials with a maximum 
value set to 1, to avoid potential overestimation of risk. 
The current prevalence of smoking was used to estimate 
PAF for the other smoking-related outcomes with a short lag 
between exposure and outcome, including cardiovascular 
conditions, respiratory tuberculosis and other respiratory 
conditions. The justification for this is that the lag between 
exposure to tobacco smoke and CVD is shorter than the lag 
for cancers and COPD. This is also reflected in the estimates 
of risk reversal after smoking cessation from the CPS-II study 
as estimated by Ezzati et al.1 – within 2 years after quitting 
smoking the risk of CVD was halved, while halving the risks 
for COPD and lung cancer occurred between 5 and 10 years 
after cessation. 
That means that the relative contribution of ex-smokers to 
the overall population risk of disease is greater for lung cancer 
and COPD than it is for CVD, since the SIR is derived from 
lung cancer rates and therefore reflects the same mix of current 
and ex-smokers contributing to disease as is relevant for lung 
cancer but not for CVD. Hence, the current prevalence of 
smoking (or the prevalence for a few years before the year of 
estimation) may be a better reflection of the relevant exposure 
for CVD, particularly if prevalence has been relatively stable 
over the recent past. 
We assume that the PAF for morbidity was the same as 
for mortality for cancers and COPD. For all other causes it 
was assumed to be half of the latter,1 arguing that tobacco 
influences not only incidence but also case fatality of these 
diseases. 
Monte Carlo simulation-modelling was used to present 
uncertainty ranges around point estimates reflecting the main 
Table III. Smoking prevalence by age group, gender and population group, South Africa, 2000 (adapted from 1998 
Demographic and Health Survey18)
                      Smoothed smoking prevalence (%) in South Africa, DHS 1998
  Indian/Asian  Black African      Coloured        White         Total
Age group (yrs) Male Female Male Female Male Female Male Female Male Female
15 - 19  28.7   10.9  11.7     0.2  26.1   20.9  31.2   36.9  15.1     5.3
20 - 24  46.4   10.9  35.7     1.2  51.6   34.5  44.6   36.8  37.9     6.8
25 - 29  58.7   10.6  49.3     3.3  64.5   43.1  50.3   35.5  51.0   10.0
30 - 34  66.1   10.0  55.3     5.7  68.9   47.8  51.1   33.7  56.4   12.8
35 - 39  69.2     9.4  56.4     7.8  68.3   49.6  48.9   31.6  56.9   14.7
40 - 44  68.6     8.8  54.4     9.4  65.5   49.5  45.3   29.5  54.5   15.7
45 - 49  65.2     8.2  51.1   10.0  62.4   47.9  41.4   27.5  50.9   15.8
50 - 54  59.7     7.6  47.6     9.7  60.4   45.4  37.9   25.6  47.2   15.4
55 - 59  52.9     7.0  44.7     8.5  60.1   42.2  35.0   23.6  44.1   13.9
60 - 64  45.8     6.3  42.5     6.7  61.2   38.4  32.5   21.2  41.8   12.1
65 - 69  39.3      5.4  41.1     4.6  63.0   33.8  29.7   18.1  40.1   10.1
70 - 74  34.5     4.0  39.8     3.0  63.8    28.2  25.3   13.6  37.3     7.8
75 - 79  32.4     2.1  37.7     2.5  61.4   21.0  17.8     7.1  33.2     5.3
80+  34.2     0.0  33.2     4.0  52.7   11.5    4.9     0.0  24.9     3.0
15+   54.8     9.0  42.4     5.0  57.2   40.0  40.4   27.7  43.7     11.1
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sources of uncertainty in the calculations. The @RISK software version 
4.5 for Excel25 allows multiple recalculations of a spreadsheet, each time 
choosing a value from distributions defined for the input variables. The 
probability distributions around the input variables were based on standard 
errors of the smoking prevalence specifying a normal distribution. For the 
RR input variables we specified a normal distribution around the natural 
logarithm of the CPS-II RR estimates.  For each of the output variables 
(namely attributable burden as a percentage of total burden in South Africa 
2000), 95% uncertainty intervals were calculated bounded by the 2.5th and 
97.5th percentiles of the 2000 iteration values generated. 
Results  
Smoking prevalence was highest among coloured and Indian males 
followed by black African males (Table III). White males and coloured 
females, with a similar smoking prevalence, were next. Among 15 - 19-
year-olds the prevalence was highest among white females. The prevalence 
increased dramatically in the 20 - 24-year age group across all population 
groups. Although white males started smoking at younger ages than black 
Africans, from 30 years and older black African men had a higher smoking 
prevalence than white men. With the exception of the 15 - 19-year age 
group, the rates for coloureds were highest across all age groups.
Table IV shows the estimated attributable fractions for all the conditions 
included in the study. Lung cancer was the outcome with the highest 
attributable fraction – 78% in males and 67% in females. This was followed 
by COPD and then upper aero-digestive cancer. Twenty-four per cent 
of tuberculosis deaths were attributed to smoking tobacco. Overall, the 
attributable fraction was 3 times higher in males than females.
Tobacco smoking caused an estimated 34 108 deaths in males (12.4% of 
all male deaths) and 10 306 deaths in females (4.2% of all female deaths) in 
South Africa in 2000 (Table IV). Since most deaths attributable to tobacco 
occurred in middle and old age, the proportion of DALYs attributable to 
tobacco was lower than the proportion of deaths (5.9% for males and 2.0% 
for females). 
Fig. 1 shows age and sex distribution for the deaths attributable to 
tobacco smoking. The deaths attributable to smoking peaked in the 45 
- 59-year age group, and at all ages there were more male than female 
deaths. Cardiovascular deaths account for the majority of tobacco-
attributable deaths, followed by COPD and then lung cancer (Fig. 2). The 
cause distribution of tobacco-attributable mortality differs between males 
and females; males have a larger proportion of deaths due to respiratory 
tuberculosis and upper aero-digestive cancers than females, while females 
have a larger proportion of deaths from cardiovascular conditions and 
COPD. 
The age-standardised tobacco-attributable mortality rates varied 
markedly between population groups and gender (Fig. 3). Coloured males 
had the highest age-standardised tobacco-attributable mortality rates, 
followed by black African and Indian males, and then white males. The 
rates for coloured females were almost as high as for white males. Rates for 
white females were about half those for coloured females. Rates for black 
African and Indian females were similar, at about one-third of the rates for 
white females. 
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The uncertainty analysis revealed that between 41 632 and  
46 656 deaths were attributable to smoking in South Africa in 
2000 (Table IV). 
Discussion 
The results of this study suggest that about 8.5% of all deaths 
and 13% of deaths in adults (> 35 years) can be attributed to 
smoking, with a large proportion of deaths (49%) occurring 
in the economically productive age groups (35 - 69 years). 
Sitas et al.8 estimated that about 8% of all adult deaths (> 
25 years) were caused by smoking in 1998, using a direct 
method of estimating tobacco-attributable mortality. This 
would translate to 34 481 smoking-attributable deaths, if the 
attributable fractions for adults > 30 years (re-estimated from 
Sitas et al.) were applied to the revised burden estimates for 
2000.16 This is remarkably similar to our indirect estimates 
of 36 841 smoking-attributable deaths, after excluding 
‘other medical causes’ and ‘other respiratory diseases’ to be 
consistent with the South African case-control study.8  We 
included ‘other medical conditions’ in line with the WHO CRA 
study,1 although evidence of an association with smoking is 
considered sufficient for only certain of these conditions by 
other researchers.26,27 This study confirms the high fraction of 
tuberculosis deaths attributed to smoking tobacco found by 
Sitas et al.8 (24% v. 20%).
The cause distribution of mortality due to smoking in South 
Africa is similar to that found in developing countries, with 
the exception of respiratory conditions. In South Africa COPD 
accounts for a smaller proportion of tobacco-attributable 
mortality (18%) than in developing countries (27%), and other 
respiratory diseases and respiratory tuberculosis account for a 
larger proportion (20% v. 13%).1 
There are marked differences in the age-standardised 
smoking-attributable mortality rates between population 
groups and genders, reflecting the differences in smoking 
prevalence between subgroups. The coloured population 
is particularly badly affected, with extremely high rates 
compared with other population groups. Of particular concern 
is the high prevalence of smoking (46%) among pregnant 
coloured women.28 Although this study did not attempt to 
measure the attributable burden due to smoking for perinatal 
conditions such as low birth weight (due to a lack of data on 
hazard size), this is likely to be substantial among coloured 
women, who have among the highest low-birth-weight rates in 
the world.   
There are clearly a number of limitations pertaining to 
indirect methods of estimating tobacco-attributed mortality. 
These include the fact that the risks of smoking in relation to 
disease increase over time, and updating the risk estimates 
using published literature depends on the availability of 
the most recent studies. Extrapolating overall risks from 
the USA to a country such as South Africa, which contains 
subpopulations that may be at different levels of the tobacco 
epidemic, may provide misleading information.29 There is also 
the risk of overestimating the hazard if there has been a sharp 
decline in smoking rates in recent years.    
There is clearly some uncertainty around these estimates, 
mainly because of the lack of reliable estimates of the RRs for 
South Africa. The CPS-II RRs as used by Peto et al.3 have the 
Fig. 1. Tobacco-attributable deaths in adults by age and sex, South Africa, 
2000.
Fig. 2.  Tobacco-attributable deaths by cause for adult males and females, 
South Africa, 2000.
Fig. 3. Age-standardised tobacco-attributable mortality rates by population 
group and gender, South Africa, 2000.
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potential to overestimate the burden since they reflect a mature 
epidemic. It is difficult to apply the RRs from South Africa,8 
India6 and China4 to the South African data since there are 
differences in inclusion and exclusion categories, for example, 
differences in aggregations of causes and age groups. However, 
crude estimates of the tobacco-attributable deaths using these 
RRs show a wide range of results (19 000 - 44 000 smoking-
attributable deaths). This may be explained by the different 
stages of the epidemic or the limitations of case-control studies. 
However, it highlights the need for more South African data to 
improve RR estimates. 
Conclusion and recommendations 
This study shows that tobacco smoking accounts for between 
12% and 15% of deaths in adults over 35 years of age in South 
Africa, from preventable disease, with at least half a million 
DALYs lost per annum. The indirect method used here yields 
very similar results to those derived from direct estimates of 
the burden of tobacco-attributed mortality in South Africa 
based on the question on a death notification form regarding 
smoking status. 
Despite some uncertainty with regard to the precise number 
of deaths attributable to smoking in South Africa, from a 
public health policy perspective these results enable tobacco- 
attributable mortality to be ranked against other risk factors, 
thus providing information for priority setting. In terms of 
mortality, tobacco ranked third (after unsafe sex/sexually 
transmitted disease and high blood pressure) out of 17 risk 
factors evaluated in the South African CRA study.30 Recent 
success in reducing smoking prevalence is likely to lower the 
burden of tobacco-attributable mortality in future decades. 
However, even at current prevalence rates, the tobacco burden 
will continue to be a large part of the burden of disease in 
South Africa. Therefore, ongoing tobacco control remains an 
important health priority in South Africa. 
Stringent tobacco control legislation and sharp increases 
in the excise tax on cigarettes illustrate the government’s 
commitment to improving tobacco control in South Africa. 
Despite increases in excise tax, the current tax burden of 52% 
of the retail price is low compared with the European Union 
minimum (57%) and the tax burdens on cigarettes sold in the 
UK and Scandinavia (more than 75%). Econometric studies 
have shown that tax and price increases, more than any other 
intervention, have decreased cigarette consumption.12 
Tobacco-control legislation is important because it affects the 
social acceptability of smoking. It changes people’s attitudes 
and rights. Whereas the right to smoke-free air was previously 
contested, the legislation has unambiguously given the right to 
smoke-free air to non-smokers.
Currently the government is debating amendments to 
the 1999 legislation.10 These entail closing some loopholes, 
increasing penalties for contravention of the existing 
legislation, banning point-of-sale adverts and introduction of 
pictorial warnings. Pictorial warnings have been introduced in 
countries like Australia, Canada and Brazil.31 These are likely 
to reach people with lower levels of education more effectively 
than written warnings. 
Other than increasing the excise tax and imposing stronger 
tobacco-control legislation, the government can reduce tobacco 
consumption through continued public education, including 
encouraging and supporting smokers to quit. Programmes 
aimed at preventing schoolchildren from starting to smoke 
need to be greatly strengthened. 
Many people still grossly underestimate the health risks 
associated with tobacco use. Quitting smoking reduces these 
risks substantially.2 Initiatives that assist smokers to quit are 
considered to be essential components of a comprehensive 
tobacco-control programme. The use of nicotine replacement 
therapies has been shown to improve the effectiveness of 
individual or group cessation efforts.32 However, the cost-
effectiveness of smoking cessation programmes and nicotine 
replacement therapies in the South African public health sector 
need to be investigated. This is an important consideration 
for the tuberculosis control programme, given that 24% of 
tuberculosis deaths can be attributed to smoking. In addition, 
it is essential that the public antenatal services develop and 
implement tobacco-cessation programmes targeted at pregnant 
women. This is particularly important for coloured women in 
view of their high smoking rates.28 In the public health sector 
health providers could support patients in making healthy 
lifestyle choices, such as quitting smoking, by providing 
a patient-centred care approach (Professor Krisela Steyn, 
South African Medical Research Council, 2006 – personal 
communication).
As a signatory to the Framework Convention on Tobacco 
Control,33 South Africa is well placed to support international 
tobacco-control activities in other developing countries and 
neighbouring states. Routine surveillance is required to 
monitor tobacco-control efforts, in particular the economic 
impact thereof. Increased cigarette smuggling could undermine 
the consumption and tax revenue impact of higher excise 
taxes, and the government needs to put measures in place to 
counteract possible smuggling. With strong tobacco-control 
measures currently in place, communities and the authorities 
should ensure that these regulations are properly monitored 
and complied with. 
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